Qingsong Zheng - Wuhan General Independent Director

WUHNDelisted Stock  USD 0.0004  0.00  0.00%   

Director

Mr. Zheng Qingsong is an Independent Director of Wuhan General Group Inc., since March 2008. Mr. Zheng has practiced law in China since 1998, and he is currently Vice Director and a partner at Hubei Junlin Law Firm. Mr. Zheng received his law degrees from Wuhan Jianhan University and Zhongnan University of Economics and Law. In 2006, Mr. Zheng was selected as a member of the Chinese Peoples Political Consultative Committee of Wuhan Hongshan District. since 2008.
Age 38
Tenure 16 years
Phone514-928-7368
Webhttps://wuhn.org

Wuhan General Management Efficiency

Wuhan General's management efficiency ratios could be used to measure how well Wuhan General manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 118.8 M in liabilities with Debt to Equity (D/E) ratio of 1.11, which is about average as compared to similar companies. Wuhan General Gr has a current ratio of 1.08, suggesting that it may not have the ability to pay its financial obligations when due. Debt can assist Wuhan General until it has trouble settling it off, either with new capital or with free cash flow. So, Wuhan General's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Wuhan General Gr sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Wuhan to invest in growth at high rates of return. When we think about Wuhan General's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Linda SanfordRelx PLC ADR
68
Carmen RomeoSEI Investments
73
Ian FraserRelx PLC ADR
N/A
Robert PoletRelx PLC ADR
59
Adrian HennahRelx PLC ADR
60
Sarah BlumensteinSEI Investments
70
Nick LuffRelx PLC ADR
49
Suzanne WoodRelx PLC ADR
60
Marike LelsRelx PLC ADR
61
Wolfhart HauserRelx PLC ADR
71
Robert MacLeodRelx PLC ADR
56
Carl GuarinoSEI Investments
60
Kathryn McCarthySEI Investments
69
Richard LiebSEI Investments
66
Chiu WongFinnovate Acquisition Corp
50
Alexander WhitelamSEI Investments
N/A
Ben VeerRelx PLC ADR
67
Lisa HookRelx PLC ADR
57
Nicholas LuffRelx PLC ADR
57
Carol MillsRelx PLC ADR
63
Vijay RaghavanRelx PLC ADR
N/A
Wuhan General Group , Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol -based products under the Dr. Wuhan General Group , Inc. is headquartered in Pointe-Claire, Canada. Wuhan General operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 700 people. Wuhan General Gr [WUHN] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading. Wuhan General is listed under Machinery category by Fama And French industry classification.

Management Performance

Wuhan General Gr Leadership Team

Elected by the shareholders, the Wuhan General's board of directors comprises two types of representatives: Wuhan General inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Wuhan. The board's role is to monitor Wuhan General's management team and ensure that shareholders' interests are well served. Wuhan General's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Wuhan General's outside directors are responsible for providing unbiased perspectives on the board's policies.
Carol Pan, Principal Officer
Yaojun Liu, Independent Director
Ruilong Qi, CEO and President Secretary and Director
Qingsong Zheng, Independent Director
Zengke Ge, General Manager
Juntao Chen, Vice President Vice General Manager - Blower
Jie Xu, Chairman of the Board
Willem Jonker, Chief Officer
Yu Shi, Independent Director
Jeffrey Robinson, Chairman Founder
Anna Morera, Chief Medical Officer
Luka MSc, Director Communication
Huang Zhaoqi, Vice Director
Johann Mcloughlin, Head Design
Shivani Subudhi, Head Marketing
Zhaoqi Huang, Vice General Manager - Turbine, Director
Ramy Kamaneh, President CEO
Li Pan, Principal Accounting Officer, Treasurer
Guoliang Liu, IR Contact
Samuel Williams, Head Foods
AAg MSc, Chief Officer

Wuhan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Wuhan General a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Note that the Wuhan General Gr information on this page should be used as a complementary analysis to other Wuhan General's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Other Consideration for investing in Wuhan Pink Sheet

If you are still planning to invest in Wuhan General Gr check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Wuhan General's history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world